Catalog No.
PAB94403
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
Golimumab
Tested applications
ELISA: 1:4000-1:8000
Target
Rabbit polyclonal to Simponi.
Specificity
The product is specific for Golimumab. This antibody serves as an excellent positive control for Golimumab immunogenicity (ADA) assays.
Concentration
0.5 mg/ml
Purification
Purified by antigen affinity column.
Accession
CAS: 476181-74-5
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
Background
Golimumab with trade name Simponi, is an FDA-approved drug for the treatment of Rheumatoid arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) and Ulcerative Colitis (UC). It is a human IgG1κ monoclonal antibody that binds to Tumor Necrosis Factor alpha (TNF-alpha), thereby inhibiting the binding to TNFα receptors and subsequent generation of inflammatory cytokines. Antibodysystem Anti-Golimumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Golimumab.
Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment-real world comparative effectiveness from German claims data., PMID:40481399
Pharmacogenomics of TNF inhibitors., PMID:40469293
The Relationship Between TNF-α Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders., PMID:40418092
Prevalence of opportunistic infections in Syrian inflammatory bowel disease patients on biologic therapy: a multi-center retrospective cross-sectional study., PMID:40320559
Diffusion dimensionality modeling of subcutaneous/intramuscular absorption of antibodies and long-acting injectables., PMID:40263185
Dual biological treatments in immune-mediated disorders: a single center experience., PMID:40200173
Rapid, Single-Step Monitoring of Monoclonal Antibody Bioavailability by Using a TNF-α-Based Multiepitope DNA Nanoswitch., PMID:40198205
Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial., PMID:40102973
Effect of TNF-α blockers on reducing the risk of dementia in rheumatoid arthritis: a nationwide cohort study., PMID:40095620
Risk of hematologic malignancies in psoriasis and rheumatoid arthritis patients using long term TNF-α inhibitors: a retrospective nationwide study., PMID:40055388
Conducting a real-world study of Tumor Necrosis factor-alpha inhibitors-induced Systemic Lupus Erythematosus based on the FAERS database., PMID:40000785
In vitro Stability Study of a Panel of Commercial Antibodies at Physiological pH and Temperature as a Guide to Screen Biologic Candidate Molecules for the Potential Risk of In vivo Asparagine Deamidation and Activity Loss., PMID:39979532
A Longitudinal Post-authorization Safety Study of Golimumab in Treatment of Ulcerative Colitis: A Cohort Study in Denmark and Sweden, 2013-2021., PMID:39913070
Construct validity and responsiveness of ASAS Health Index assessed in two longitudinal studies of tumour necrosis factor alpha inhibitor initiation and dose reduction in patients with axial spondyloarthritis., PMID:39794273
Treatment Persistence Among Anti-Tumor Necrosis Factor-experienced Patients With Ulcerative Colitis Switching to a Biologic With a Different Mode of Action or Cycling to Another Anti-Tumor Necrosis Factor Agent., PMID:39743427
Effectiveness and Treatment Persistence of Vedolizumab Compared to Anti-Tumour Necrosis Factor-α in Patients With Crohn's Disease: A Systematic Literature Review and Meta-Analysis., PMID:39707930
Interactions of warfarin with COVID-19 vaccine/drugs, monoclonal antibodies, and targeted anticancer agents from real-world data mining., PMID:39679378
Golimumab-Induced Anti-NuMA-1 (Nuclear Mitotic Apparatus Protein 1) Antibodies in a Rheumatoid Arthritis Patient: A Case Report., PMID:39628740
Collaborative study for the establishment of Golimumab Biological Reference Preparation Batch 1., PMID:39625655
TNFα-inhibitors cycling with golimumab as second drug in inflammatory arthritis patients: Data from the multicenter GO-REAL registry., PMID:39617528
Innovation in Alopecia Areata., PMID:39542562
Factors Associated with the Development of Anti-drug Antibodies to TNFi and the Consequences for Axial Spondyloarthritis: A Two-year Follow-up Study., PMID:39479725
Factors influencing the discontinuation of biologic therapies in patients with ulcerative colitis., PMID:39425179
Incidence and risk factors of discontinuation of tofacitinib and biologic disease-modifying anti-rheumatic drugs among patients with rheumatoid arthritis: A population-based cohort study., PMID:39392514
Therapeutic drug monitoring in inflammatory bowel disease: recent developments., PMID:39382556
Efficacy and safety of mirikizumab compared with currently approved biologic drugs for the treatment of ulcerative colitis: A systematic review and network meta-analysis., PMID:39320112
Monoclonal antibodies against pediatric ulcerative colitis: a review of clinical progress., PMID:39285823
Case report: Crescentic IgA nephropathy with anti-neutrophil cytoplasmic antibodies, in a patient on golimumab., PMID:39239851
[Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-Tumor Necrosis Factors]., PMID:39176459
Targeted therapies and conventional care for the treatment of ankylosing spondylitis in China: a cost-effectiveness analysis based on the network-meta analysis., PMID:39155381
Persistence of advanced systemic pharmacological treatment of moderate-to-severe psoriasis among bio-naïve patients-A retrospective register-based cohort study in Finland and Sweden., PMID:39092632
Pregnancy and Infant Outcomes After Prenatal Exposure to Golimumab in Denmark, Finland, and Sweden 2006-2019., PMID:39090766
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study., PMID:39089836
Newer Therapies in Rheumatology., PMID:39084836
TNF-alpha Inhibitors Induced Eosinophilia: A Case Report of an Undervalued Side Effect of Such Biologicals., PMID:39041261
Safety of TNF-α inhibitors: A real-world study based on the US FDA Adverse Event Reporting System Database., PMID:39029031
Concurrent occurrence of ulcerative duodenitis and ulcerative colitis displaying unique responses to golimumab and ustekinumab., PMID:39023824
Exposure to golimumab during pregnancy: Results from the Company's global safety database., PMID:38970433
Merkel cell carcinoma associated with TNF inhibitor therapy: a systematic review of case reports., PMID:38959915
Yellow discoloration of the fingers due to golimumab with dermoscopic features: A brief literature review., PMID:38881330
Cardiovascular Adverse Events Associated with Tumor Necrosis Factor-Alpha Inhibitors: A Real-World Pharmacovigilance Analysis., PMID:38866553
[Ulcerative colitis diagnosed with facial pyoderma gangrenosum: a case report]., PMID:38853017
Efficacy of golimumab in rheumatoid arthritis patients at high risk of a poor prognosis: Post hoc analysis of GO-FORTH study using cluster analysis., PMID:38780239
[Head-to-head studies on radiographic progression in axial spondyloarthritis]., PMID:38771349
Neurological disorders following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: a real-world pharmacovigilance analysis., PMID:38769926
Drug Persistence and Incidence of Active Tuberculosis of Tumor Necrosis Factor Alpha Inhibitors Versus Tocilizumab as the First-Line Biological Treatment in Patients with Rheumatoid Arthritis: A Nationwide Population-Based Retrospective Cohort Analysis., PMID:38769252
Safety and Efficacy of Golimumab in Indian Patients with Active Spondyloarthritis of Ankylosing Spondylitis or Psoriatic Arthritis: A Multicenter, Noncomparative, Open-Label, Real-World Study., PMID:38736116
Disease modification in axial spondyloarthritis - still a controversy?, PMID:38712691
Efficacy and safety of biological treatment for inflammatory bowel disease in elderly patients: Results from a GETECCU cohort., PMID:38710465
For research use only. Not for human or drug use.
